Bayer

Contact Us

Congress Library

American College of Cardiology 2025

Posters

Agarwal mechanisms of cardiovascular benefit Agarwal mechanisms of cardiovascular benefit

Rajiv Agarwal

Mechanisms of Cardiovascular Benefit with Finerenone—A Causal Mediation Analysis of the Joint Effects of Systolic Blood Pressure and Albuminuria Reduction

Click to access
Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure

Jawad H. Butt

Finerenone, Chronic Obstructive Pulmonary Disease, and Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial

Click to access
Finerenone, Liver Biomarkers and Heart Failure With Mildly Reduced or Preserved Ejection Fraction Finerenone, Liver Biomarkers and Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Jawad H. Butt

Finerenone, Liver Biomarkers and Heart Failure With Mildly Reduced or Preserved Ejection Fraction: An Analysis of the FINEARTS-HF Trial

Click to access
Efficacy of Finerenone According to Left Atrial Size in Patients with Heart Failure Efficacy of Finerenone According to Left Atrial Size in Patients with Heart Failure

Misato Chimura

Efficacy of Finerenone According to Left Atrial Size in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: An Analysis of the FINEARTS-HF Trial

Click to access
Efficacy and Safety of Finerenone in Patients with Heart Failure Efficacy and Safety of Finerenone in Patients with Heart Failure

Misato Chimura

Efficacy and Safety of Finerenone in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Anemia-specific Analysis of the FINEARTS-HF Trial

Click to access
Effects of Finerenone on Natriuretic Peptide Levels in Heart Failure Effects of Finerenone on Natriuretic Peptide Levels in Heart Failure

Jonathan W. Cunningham

Effects of Finerenone on Natriuretic Peptide Levels in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Click to access
Mode of Death in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial Mode of Death in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Akshay S. Desai

Mode of Death in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial

Click to access
Worsening Heart Failure in Adults with Mild-to-Moderate Chronic Kidney Disease Worsening Heart Failure in Adults with Mild-to-Moderate Chronic Kidney Disease

Michael P. Girouard

Worsening Heart Failure in Adults with Mild-to-Moderate Chronic Kidney Disease

Click to access
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Henri Lu

Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Click to access
Finerenone and Atrial Fibrillation in Heart Failure: A Prespecified Analysis of FINEARTS-HF Finerenone and Atrial Fibrillation in Heart Failure: A Prespecified Analysis of FINEARTS-HF

Shingo Matsumoto

Finerenone and Atrial Fibrillation in Heart Failure: A Prespecified Analysis of FINEARTS-HF

Click to access
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial

John W. Ostrominski

Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial

Click to access
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial

John W. Ostrominski

Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial

Click to access
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolism: The FINE-HEART Pooled Analysis Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolism: The FINE-HEART Pooled Analysis

Maria A. Pabon

Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolism: The FINE-HEART Pooled Analysis

Click to access

Follow Us

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Copyright © 2024 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap